Working hours24*7 AvailableCall us+91 9967979080
Capivasertib tablets

Capivasertib

Generic Name/API:Capivasertib
Packaging:64 film coated tablets, each 160 mg or 200mg
Storage:20°C to 25°C (68°F to 77°F).
Dosage:For dosage information, please check the General Information section.
Strength:Each tablet: 160 mg or 200 mg
Indication:Capivasertib is a kinase inhibitor, taken in combination with fulvestrant to treat HR+/HER- locally advanced or metastatic breast cancer with one or more mutations in PIK3CA, AKT1 or PTEN genes, post progression after endocrine therapy in metastatic cancer or recurrence on or within 12 months of completing adjuvant therapy.

TRUQAP or capivasertib is a serine/threonine kinase inhibitor which blocks enzymatic activity of serine/threonine kinase AKT 1, 2, and 3, which play a role in proliferation of cancer cells with mutations in PIK3CA, AKT1 or PTEN genes. Thus, it will reduce the growth of cancer cells. It is  indicated, in combination with fulvestrant (anti-oestrogen medicine) for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-mutations (as detected by an FDA-approved test) following progression on at least one endocrine-based regimen like aromatase inhibitor (to reduce estrogen levels)  in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. In pre-menopausal or perimenopausal women, capivasertib should be accompanied with luteinising hormone agonist, to lower blood levels of oestrogen and progesterone. 

STRENGTH 

  • Each tablet: 160 mg or 200 mg 

DOSAGE:  

Recommended dosage: 

  • 400 mg orally 2 times daily, 12 hours apart, with or without food. Tablets are to be taken for 4 consecutive days followed by 3 days off.  Fulvestrant is to be given on days 1, 15 and 29, and once monthly thereafter. 

Dosage reductions for adverse reactions: 

  • First dose reduction: 320 mg twice daily for 4 days followed by 3 days off
  • Second dose reduction: 200 mg twice daily for 4 days followed by 3 days off

SIDE EFFECTS 

  • The most common adverse reactions of capivasertib use that have an  an  incidence of 20% or greater, are diarrhea, cutaneous adverse reactions, increased random glucose or hyperglycemia, decreased lymphocytes, decreased hemoglobin, increased fasting glucose, nausea, fatigue, decreased leukocytes, increased triglycerides, decreased neutrophils, increased creatinine, vomiting and stomatitis. 

STORAGE :

  • Store capivasertib in original packaging to maintain stability at 20°C to 25°C (68°F to 77°F). Excursions permitted to 15°C to 30°C (59°F to 86°F). 
  1. Hyperglycemia: Evaluate blood glucose and HbA1c levels before initiating capivasertib and monitor regularly during treatment. Severe hyperglycemia, including cases with ketoacidosis, has occurred in patients under capivasertib treatment. The safety of capivasertib in patients with Type 1 diabetes or insulin-dependent diabetes is unknown. Inform patients about the risk of hyperglycemia and instruct them to contact a healthcare professional if symptoms such as excessive thirst, frequent urination, or unexplained weight loss occur. Monitor fasting glucose every two weeks during the first month and monthly thereafter. Check HbA1c every three months.
  2. Diarrhea: (occurs in 72% patients) Severe diarrhea with dehydration occurred in patients receiving capivasertib. Monitor for symptoms and advise patients to increase oral fluids and start antidiarrheals at the first sign of diarrhea.
  3. Cutaneous Adverse Reactions: (occurs in 58% patients) Skin reactions, including serious events like erythema multiforme, palmar-plantar erythrodysesthesia, and DRESS or drug reaction with eosinophilia and systemic symptoms , occurred in patients under treatment with capivasertib . Monitor for symptoms and consider early dermatology consultation if required. Corticosteroids may be prescribed based on severity.
  4. Embryo-Fetal Toxicity: Capivasertib can cause fetal harm. Based on animal studies and known MOA, embryo-fetal death and reduced fetal weight were observed at maternal exposures 0.7 times the recommended human dose (400 mg twice daily). Advise pregnant women and females of reproductive potential of the associated risk. Recommend effective contraception for both females under treatment and male partners (during treatment and for 1 month after the last dose for females, and for 4 months after the last dose for males with female partners). Capivasertib is used in combination with fulvestrant.

Procedure to deliver medicine on time

FAQ

  • What is capivasertib ?
  • What is capivasertib used for?
  • What are the common side effects of capivasertib use?
  • Can Capivasertib be used in specific populations such as pregnant, breastfeeding, pediatric, or geriatric patients?
  • What is the cost of Truqap (Capivasertib) 160mg & 200mg Tablet in India?
  • How to buy Truqap (Capivasertib) 160mg & 200mg tablets in India?
  • What are the key criteria for selecting a supplier?
What is capivasertib ?

 TRUQAP or capivasertib is a serine/threonine kinase inhibitor which blocks enzymatic activity of serine/threonine kinase AKT 1, 2, and 3, which play a role in proliferation of cancer cells with mutations in PIK3CA, AKT1 or PTEN genes. Thus, it will reduce the growth of cancer cells.

What is capivasertib used for?

Capivasertib is used to treat HR+/HER- locally advanced or metastatic breast cancer with one or more mutations in PIK3CA, AKT1 or PTEN genes, post progression after endocrine therapy in metastatic cancer or recurrence on or within 12 months of completing adjuvant therapy.

What are the common side effects of capivasertib use?

Common side effects of Capivasertib include diarrhea, skin reactions, and increased blood glucose levels (hyperglycemia).

Can Capivasertib be used in specific populations such as pregnant, breastfeeding, pediatric, or geriatric patients?

Capivasertib may cause fetal harm and should be avoided in pregnancy and breastfeeding. A negative pregnancy test is required before starting, and effective contraception must be used during treatment and for 4 months after the last dose. Not established as safe in pediatric patients. No efficacy differences in those ≥65, but higher rates of adverse reactions and treatment modifications. No dose changes needed for mild/moderate kidney or liver impairment; severe cases not studied.

What is the cost of Truqap (Capivasertib) 160mg & 200mg Tablet in India?

The cost of Truqap (Capivasertib) 160 mg & 200 mg tablets in India varies as it must be imported. Pricing depends on factors such as currency exchange rates, import duties, and supplier availability. For the latest cost and order details, please contact 24/7 QualityMeds.

How to buy Truqap (Capivasertib) 160mg & 200mg tablets in India?

To buy Truqap (Capivasertib) 160 mg & 200 mg tablets in India at a genuine price, contact 24/7 QualityMeds. Our team helps you import this medicine legally and at the best possible cost.

What are the key criteria for selecting a supplier?

While selecting a supplier, we essentially ensure that the supplier holds a valid Good Distribution Practice (GDP) certificate and possesses a valid operating license. These credentials confirm that the suppliers adherence to International standards for the proper distribution of medicinal product

"I am very happy with experience of delivery medicine! From start to finish, everything was smooth, professional, and exceeded my expectations. The coordinator was incredibly responsive and friendly, and the product itself best in condition exactly as described. Delivery was fast, packaging was secure, and I felt truly valued as a customer. I’ll be coming back and recommending this to friends and family. Once again Thanks for delivering medicine with in 24 hours which help my wife to start treatment on time. "

- Mr. Sanjay More

"I’ve been using this medicine delivery service for a few months now, and I couldn’t be happier. The ordering process is simple and user-friendly, and the delivery is always prompt and reliable. I especially appreciate the timely updates, which help me stay on track with my prescriptions. The coordinator team is responsive and genuinely helpful, always ready to answer questions or resolve any issues. The packaging is secure, and the medicines always arrive in perfect condition. This service has made managing my health so much easier and stress-free. Highly recommended for anyone looking for convenience, reliability, and great customer care! "

- Mr. Nilesh Patankar

"I’m really impressed with the level of service. From placing the order to receiving the medicines, everything is smooth and hassle-free. The coordinator even called several times for updates my package. It’s rare to find such thoughtful service these days!"

- Mr. Mohit Vishwakarma

About us

We're a dedicated team of medicine access experts, doctors and pharmacists. We come from all over the world. And we've lost family and friends who could not get the medicine they needed because they lived in the wrong country.

Our mission is to get everyone the right treatment at the right time. Wherever you live. Because you should not suffer or die if a treatment that could help you exists somewhere.

Learn more ›

If you have any questions or need help, we're a phone call away. Our team is available from Monday to Friday between 9 a.m and 6 p.m CET

We usually respond to emails within 24 working hours

Worldwide Delivery

Afghanistan, Albania, Algeria, American Samoa, Angola, Anguilla, Antarctica, Antigua & Barbuda, Armenia, Aruba, Australia, Austria, Azerbaijan, Bahamas, Bahrain, Bangladesh, Barbados, Belarus, Belgium, Belize, Benin, Bermuda, Bhutan, Bolivia, Bosnia & Herzegovina, Botswana, Bouvet Island, Brazil, British Indian Ocean Territory, British Virgin Islands, Brunei, Bulgaria, Burkina Faso, Burundi, Cambodia, Cameroon, Canada, Cape Verde, Cayman Islands, Central African Republic, Chad, Chile, China, Christmas Island, Cocos (Keeling) Islands, Colombia, Comoros, Congo - Brazzaville, Congo - Kinshasa, Cook Islands, Costa Rica, Croatia, Cuba, Cyprus, Czechia, Côte d'Ivoire, Denmark, Djibouti, Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Estonia, Eswatini, Ethiopia, Falkland Islands, Faroe Islands, Fiji, Finland, France, French Guiana, French Polynesia, French Southern Territories, Gabon, Gambia, Georgia, Germany, Ghana, Gibraltar, Greece, Greenland, Grenada, Guadeloupe, Guam, Guatemala, Guernsey, Guinea, Guinea-Bissau, Guyana, Haiti, Heard & McDonald Islands, Honduras, Hong Kong SAR China, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Isle of Man, Israel, Italy, Jamaica, Japan, Jersey, Jordan, Kazakhstan, Kenya, Kiribati, Kuwait, Kyrgyzstan, Laos, Latvia, Lebanon, Lesotho, Liberia, Libya, Liechtenstein, Lithuania, Luxembourg, Macao SAR China, Madagascar, Malawi, Malaysia, Maldives, Mali, Malta, Marshall Islands, Martinique, Mauritania, Mauritius, Mayotte, Mexico, Micronesia, Moldova, Monaco, Mongolia, Montenegro, Montserrat, Morocco, Mozambique, Myanmar (Burma), Namibia, Nauru, Nepal, Netherlands, New Caledonia, New Zealand, Nicaragua, Niger, Nigeria, Niue, Norfolk Island, North Korea, North Macedonia, Northern Mariana Islands, Norway, Oman, Pakistan, Palau, Palestinian Territories, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Pitcairn Islands, Poland, Portugal, Qatar, Romania, Russia, Rwanda, Réunion, Saint Barthélemy, Samoa, San Marino, Saudi Arabia, Senegal, Serbia, Seychelles, Sierra Leone, Singapore, Slovakia, Slovenia, Solomon Islands, Somalia, South Africa, South Georgia & South Sandwich Islands, South Korea, Spain, Sri Lanka, St. Helena, St. Kitts & Nevis, St. Lucia, St. Martin, St. Pierre & Miquelon, St. Vincent & Grenadines, Sudan, Suriname, Svalbard & Jan Mayen, Sweden, Switzerland, Syria, São Tomé & Príncipe, Taiwan, Province of China, Tajikistan, Tanzania, Thailand, Timor-Leste, Togo, Tokelau, Tonga, Trinidad & Tobago, Tunisia, Turkey, Turkmenistan, Turks & Caicos Islands, Tuvalu, U.S. Outlying Islands, U.S. Virgin Islands, Uganda, Ukraine, United Arab Emirates, United Kingdom, United States, Uruguay, Uzbekistan, Vanuatu, Vatican City, Venezuela, Vietnam, Wallis & Futuna, Western Sahara, Yemen, Zambia, Zimbabwe, Åland Islands

Disclaimer

All trademarks, logos, brand names, and product names appearing on this website are the property of their respective owners. 247qualitymeds.com does not claim any ownership or affiliation with these trademarks or brands. They are used solely for informational and reference purposes to help users identify products and understand their intended use. The presence of any trademark or brand name on this website does not imply endorsement, sponsorship, or association with 247qualitymeds.com in any form.